These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 26339744)

  • 1. Response to the Letter by Zhou, et al.
    Liu M; Fang ZY; Yang Q
    J Clin Endocrinol Metab; 2015 Sep; 100(9):L80-1. PubMed ID: 26339744
    [No Abstract]   [Full Text] [Related]  

  • 2. Management of nicotinamide N-methyltransferase overexpression: inhibit the enzyme or reduce nicotinamide intake? Reply to Zhou S, Li D, Zhou Y [letter].
    Kannt A; Pfenninger A; Tönjes A; Blüher M
    Diabetologia; 2015 Sep; 58(9):2193-4. PubMed ID: 26113421
    [No Abstract]   [Full Text] [Related]  

  • 3. Letter to the Editor: High Serum N(1)-Methylnicotinamide in Obesity and Diabetes: A Consequence of Excess Nicotinamide?
    Zhou SS; Li D; Zhou Y
    J Clin Endocrinol Metab; 2015 Sep; 100(9):L78-9. PubMed ID: 26339743
    [No Abstract]   [Full Text] [Related]  

  • 4. Management of nicotinamide N-methyltransferase overexpression: inhibit the enzyme or reduce nicotinamide intake?
    Zhou SS; Li D; Zhou Y
    Diabetologia; 2015 Sep; 58(9):2191-2. PubMed ID: 26122878
    [No Abstract]   [Full Text] [Related]  

  • 5. Association of nicotinamide-N-methyltransferase mRNA expression in human adipose tissue and the plasma concentration of its product, 1-methylnicotinamide, with insulin resistance.
    Kannt A; Pfenninger A; Teichert L; Tönjes A; Dietrich A; Schön MR; Klöting N; Blüher M
    Diabetologia; 2015 Apr; 58(4):799-808. PubMed ID: 25596852
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Analysis of changes in the serum levels of lipids and lipoproteins in obese persons and in patients with diabetes mellitus type 2 associated with obesity].
    Jakubczyk D; Borejszo I; Kinalska I; Szelachowska M; Biedzińska M
    Pol Tyg Lek; 1985 Dec; 40(50):1395-7. PubMed ID: 3831988
    [No Abstract]   [Full Text] [Related]  

  • 7. Serum visfatin is associated with type 2 diabetes mellitus independent of insulin resistance and obesity.
    Esteghamati A; Alamdari A; Zandieh A; Elahi S; Khalilzadeh O; Nakhjavani M; Meysamie A
    Diabetes Res Clin Pract; 2011 Feb; 91(2):154-8. PubMed ID: 21122936
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adipokines and vascular risk in type 2 diabetes mellitus.
    Katsiki N; Yovos JG; Gotzamani-Psarrakou A; Karamitsos DT
    Angiology; 2011 Nov; 62(8):601-4. PubMed ID: 21990548
    [No Abstract]   [Full Text] [Related]  

  • 9. What do we (not) know about apoB, type 2 diabetes and obesity?
    Smith J; Amri MA; Sniderman AD
    Diabetes Res Clin Pract; 2005 Jul; 69(1):99-101. PubMed ID: 15955392
    [No Abstract]   [Full Text] [Related]  

  • 10. [Effect of body mass reduction on the level of adiponectin in patients with obesity and type 2 diabetes mellitus].
    Roĭtman AP; Dolgov VV; Selivanova AV; Iakovlev VN
    Klin Med (Mosk); 2012; 90(12):46-7. PubMed ID: 23516870
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Response to the Letter by Kalra S. et al.
    Kramer CK; Zinman B; Retnakaran R
    J Clin Endocrinol Metab; 2015 Nov; 100(11):L118. PubMed ID: 26544664
    [No Abstract]   [Full Text] [Related]  

  • 12. Obese type 2 diabetes mellitus patients have higher serum vaspin concentrations.
    Dai R; Dong Z; Qian Y; Han Y
    J Diabetes; 2016 May; 8(3):445-7. PubMed ID: 26676943
    [No Abstract]   [Full Text] [Related]  

  • 13. Serum visfatin in relation to visceral fat, obesity, and type 2 diabetes mellitus in Asian Indians.
    Sandeep S; Velmurugan K; Deepa R; Mohan V
    Metabolism; 2007 Apr; 56(4):565-70. PubMed ID: 17379018
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Changes of blood fatty acid in women with obesity and type 2 diabetes mellitus].
    Mikaelyan NP; Terentev AA; Nguen KH; Mikaelyan AV; Novikova SA
    Biomed Khim; 2015; 61(6):760-4. PubMed ID: 26716749
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circulating sclerostin levels and cardiovascular risk in obesity.
    Popovic DS; Stokic E; Tomic-Naglic D; Novakovic-Paro J; Mitrovic M; Vukovic B; Kovacev-Zavisic B
    Int J Cardiol; 2016 Jul; 214():48-50. PubMed ID: 27057975
    [No Abstract]   [Full Text] [Related]  

  • 16. Increased glycemic variability at the onset and during progression of type 2 diabetes-commentary.
    Rodbard D
    Diabetes Technol Ther; 2013 Jun; 15(6):445-7. PubMed ID: 23731442
    [No Abstract]   [Full Text] [Related]  

  • 17. [Change and correlated factors of fasting level of the plasma endotoxin in subjects with different glucose tolerances and body mass indices].
    Liu YH; Zhao TY; Hou LQ
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2013 Sep; 44(5):769-73, 778. PubMed ID: 24325109
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Letter to the Editor: "Steroid Sex Hormones, Sex Hormone-Binding Globulin, and Diabetes Incidence in the Diabetes Prevention Program" by Mather K.J., et al.
    Mauvais-Jarvis F
    J Clin Endocrinol Metab; 2015 Dec; 100(12):L126-7. PubMed ID: 26642271
    [No Abstract]   [Full Text] [Related]  

  • 19. [Comparison of blood sugar and insulin reactions of obese and non-obese patients with NIDDM].
    Wang H; Wu H
    Zhonghua Yi Xue Za Zhi; 1989 Nov; 69(11):631-2. PubMed ID: 2699824
    [No Abstract]   [Full Text] [Related]  

  • 20. Letter to the Editor: Comment on "The Impact of Chronic Liraglutide Therapy on Glucagon Secretion in Type 2 Diabetes: Insight From the LIBRA Trial" by Kramer C.K., et al.
    Kalra S; Gupta Y
    J Clin Endocrinol Metab; 2015 Nov; 100(11):L116-7. PubMed ID: 26544663
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.